Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Relmada Therapeutics stock | $35

Own Relmada Therapeutics stock in just a few minutes.

Fact checked

Relmada Therapeutics, Inc is a drug manufacturers-specialty & generic business based in the US. Relmada Therapeutics shares (RLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Relmada Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of USD$570.2 million.

How to buy shares in Relmada Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Relmada Therapeutics. Find the stock by name or ticker symbol: RLMD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Relmada Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$35, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Relmada Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Relmada Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Relmada Therapeutics share price

Use our graph to track the performance of RLMD stocks over time.

Relmada Therapeutics shares at a glance

Information last updated 2020-12-10.
Latest market closeUSD$35
52-week rangeUSD$23.25 - USD$52.215
50-day moving average USD$33.6343
200-day moving average USD$38.8683
Wall St. target priceUSD$62.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.6788

Buy Relmada Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Titan
Titan
$0
Stocks, Bonds
N/A
1%
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Relmada Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Relmada Therapeutics price performance over time

Historical closes compared with the close of $35 from 2020-12-09

1 week (2021-01-11) N/A
1 month (2020-12-22) 6.38%
3 months (2020-10-18) N/A
6 months (2020-07-18) N/A
1 year (2020-01-18) N/A
2 years (2019-01-18) N/A
3 years (2018-01-18) N/A
5 years (2016-01-18) N/A

Relmada Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -158.57%
Return on equity TTM 0%
Profit margin 0%
Book value $7.549
Market capitalisation USD$570.2 million

TTM: trailing 12 months

Shorting Relmada Therapeutics shares

There are currently 1.0 million Relmada Therapeutics shares held short by investors – that's known as Relmada Therapeutics's "short interest". This figure is 0.8% up from 998,616 last month.

There are a few different ways that this level of interest in shorting Relmada Therapeutics shares can be evaluated.

Relmada Therapeutics's "short interest ratio" (SIR)

Relmada Therapeutics's "short interest ratio" (SIR) is the quantity of Relmada Therapeutics shares currently shorted divided by the average quantity of Relmada Therapeutics shares traded daily (recently around 78834.76898982). Relmada Therapeutics's SIR currently stands at 12.77. In other words for every 100,000 Relmada Therapeutics shares traded daily on the market, roughly 12770 shares are currently held short.

However Relmada Therapeutics's short interest can also be evaluated against the total number of Relmada Therapeutics shares, or, against the total number of tradable Relmada Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Relmada Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Relmada Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0619% of the tradable shares (for every 100,000 tradable Relmada Therapeutics shares, roughly 62 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Relmada Therapeutics.

Find out more about how you can short Relmada Therapeutics stock.

Relmada Therapeutics share dividends

We're not expecting Relmada Therapeutics to pay a dividend over the next 12 months.

Have Relmada Therapeutics's shares ever split?

Relmada Therapeutics's shares were split on a 1:4 basis on 30 September 2019. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Relmada Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Relmada Therapeutics shares which in turn could have impacted Relmada Therapeutics's share price.

Relmada Therapeutics share price volatility

Over the last 12 months, Relmada Therapeutics's shares have ranged in value from as little as $23.25 up to $52.215. A popular way to gauge a stock's volatility is its "beta".

RLMD.US volatility(beta: 0.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Relmada Therapeutics's is 0.6341. This would suggest that Relmada Therapeutics's shares are less volatile than average (for this exchange).

Relmada Therapeutics overview

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site